Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS.

The official launch of MyPRS will take place at the 52nd Annual American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida on December 4th. As part of the product launch the company will begin executing a commercialization plan that includes offering the test to physicians through a direct salesforce and via select specialty commercial laboratories.  The test will be performed at the company’s CLIA certified laboratory.

Myeloma Prognostic Risk Signature (MyPRS) offers the most detailed expression profiling information for Multiple Myeloma patients available on the market. MyPRS analyzes and applies a proprietary algorithm to a defined number of relevant genes to determine the gene expression profile (GEP) associated with the patient’s condition. The gene expression profiling behind MyPRS allows physicians to gain a predictive view of their patient’s prognosis, enabling truly personalized treatment options.

“At Signal Genetics our goal is to make truly personalized treatments a reality, and with the launch of MyPRS, that goal is brought one step closer to being achieved,” said CEO, Joe Hernandez. “MyPRS is backed by robust science, the technology has been published in over 70 peer reviewed scientific journals, it uses the world’s largest outcomes database to correlate patient disease profiles, and provides additional insights to a patient’s specific Gene Expression Profile (GEP) beyond today’s current FISH and Cytogenetic based assays.”

According to Dr Kenneth Anderson, chief of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, Harvard Medical School and member of Signal Genetics’ Scientific Advisory Board, “Gene expression profiling has great potential to offer personalized medicine to patients with myeloma.”

Signal Genetics, the parent company of Myeloma Health, is a privately held predictive genetic testing company focused on helping cancer patients. The goal of Signal Genetics is to provide cancer patients and their physicians with novel and innovative insights into their disease, including predictive outcome of disease stage, odds of relapse, and the optimal treatment regimen based on their specific genetic expression profile.